Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Aug 09, 2026
Lightwave Logic (LWLG) +18.7% Rebound in 30 Days: CFO Hire and Earnings Call in Focus

Lightwave Logic (LWLG) +18.7% Rebound in 30 Days: CFO Hire and Earnings Call in Focus

Key Takeaways

  • Lightwave Logic shares climbed approximately 18.7% over the last 30 days, recovering from a late-July trough of $5.345 to close at $8.11 on August 7, 2026.
  • The appointment of Fred Graffam, a seasoned telecom finance executive, as Chief Financial Officer on July 20 helped stabilize sentiment during a volatile stretch.
  • Anticipation ahead of the company's Q2 2026 earnings and business update call, scheduled for August 11, fueled the sharpest gains in early August.
  • Despite the 30-day rally, LWLG remains down roughly 52% over the broader quarter, reflecting the scale of the sell-off that preceded the rebound.
  • The company's long-term investment narrative remains anchored to its electro-optic polymer platform and its role in next-generation AI data center infrastructure.

Lightwave Logic (LWLG) Company Overview and Market Position

Lightwave Logic, Inc. is a technology platform company that develops proprietary electro-optic polymer materials designed to transmit data at higher speeds with lower power consumption than conventional technologies. Its Perkinamine polymer platform targets next-generation photonic devices used in telecommunications, data center interconnects, and AI infrastructure. The company operates a capital-light, fabless business model centered on technology licensing, material sales, and reference design services, partnering with semiconductor foundries such as TSEM to integrate its modulator technology into established silicon photonics manufacturing workflows. Investors follow LWLG for its exposure to the rapidly expanding AI-driven optical networking market, where management estimates a serviceable addressable market of $2 billion to $4 billion. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Lightwave Logic (LWLG) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, LWLG shares delivered a gain of approximately 18.7%, moving from a closing price of $6.83 on July 10 to $8.11 on August 7. The path was far from linear: the stock slid to an intra-period low of $5.345 on July 29 before staging a vigorous recovery. The rebound accelerated in early August, with the stock surging from $6.82 on August 3 to $7.95 on August 4 on more than double the average daily volume.

The quarterly picture remains significantly more challenging. Approximately 90 days ago, LWLG closed at $16.86 on May 11, meaning the stock has declined roughly 52% over the broader quarter. That decline reflects a punishing multi-month sell-off from the 52-week high of $18.71 reached on May 13, driven by a combination of a wider-than-expected Q1 2026 net loss, a shelf registration filing, broad weakness across optical and photonics stocks, and profit-taking following the stock's inclusion in Russell indexes earlier in the year.

What Drove LWLG Stock Price in the Last 30 Days

The most significant catalyst during the 30-day period was the appointment of Fred Graffam as Chief Financial Officer, announced on July 20. Graffam brings more than two decades of financial leadership experience, including CFO roles at Consolidated Communications (CNSL), Ascent Capital Group, and senior finance positions at DigitalGlobe and Level 3 Communications. His telecom and infrastructure background was well-received by investors seeking stronger financial stewardship as the company advances toward commercialization. In his introductory statement, Graffam noted that Lightwave Logic "has the potential to play a critical role in the current AI investment cycle," reinforcing the core bull thesis.

The second major catalyst came on August 3, when the company announced it would host its Q2 2026 financial results and business update call on August 11. The announcement ignited a sharp rally, with the stock leaping 16.6% on August 4 on volume exceeding 3.5 million shares — roughly double the average daily turnover. The market appeared to price in optimism that the call would bring positive updates on customer engagements, foundry tape-out progress, or potential licensing agreements.

Additionally, the stock appeared deeply oversold by late July after falling from its May highs above $18 to below $5.50, creating conditions for a technical bounce. Sector-wide sentiment also improved in early August as broader technology and AI-related names recovered from the mid-July sell-off that had pressured the optical and photonics group.

What Drove LWLG Stock Performance Over the Last Quarter

The broader quarterly decline of approximately 52% from mid-May levels was shaped by several converging headwinds. In May, the stock tumbled from its 52-week high of $18.71 after first-quarter 2026 results revealed a wider net loss of $6.3 million and negligible revenue of roughly $29,000, reminding the market that LWLG remains a pre-revenue development-stage company. The concurrent filing of a shelf registration covering 402,500 existing shares amplified dilution concerns.

The sell-off was compounded by a broader rotation out of high-beta, pre-profit technology names as macro uncertainty weighed on risk appetite. Optical and photonics stocks, including LWLG, faced additional pressure from investor concerns about foundry capacity constraints and extended commercialization timelines. Even positive developments — such as the Tower Semiconductor development agreement announced in March and Russell index inclusion — were largely priced in by May, leaving the stock vulnerable to profit-taking when momentum faded.

The appointment of a new CFO and the impending Q2 earnings call have begun to shift the narrative, but the quarterly performance underscores the stock's high sensitivity to execution milestones and sentiment swings.

LWLG Stock Forecast Drivers: What Investors Should Watch Next

The most immediate catalyst is the Q2 2026 earnings and business update call on August 11. Investors will closely scrutinize any updates on the four Fortune 500 and Fortune Global 500 customers currently in the prototyping phase, progress on engineering tape-outs with Tower Semiconductor, and any movement toward a material supply or licensing agreement with lead customers. Management commentary on foundry capacity constraints, which have been a recurring bottleneck, will be equally important.

Beyond the earnings call, the back half of 2026 is expected to bring multiple engineering tape-outs that could validate the performance and manufacturability of the company's polymer modulator technology. Any announcements of new customer design wins, partnership expansions, or progress toward the anticipated 2027 commercial revenue timeline could move the stock meaningfully. On the risk side, investors should monitor cash burn rates, potential capital raises, insider selling activity, and the broader interest-rate environment, which heavily influences speculative pre-revenue technology valuations. From what I see, this earnings update could set the tone for the remainder of the year.

Using Tickeron’s AI Tools for Market Analysis

In my research on stocks like LWLG, I’ve turned to Tickeron’s AI Trading Bots to explore systematic approaches that complement fundamental analysis. These tools help identify patterns and trends across a wide range of securities, offering an additional layer of perspective for traders navigating volatile sectors such as photonics and AI infrastructure. One thing that stands out is how they can surface opportunities during periods of sharp price swings without replacing core due diligence.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: LWLG

Contributor

<p>Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years&nbsp;developing&nbsp;his proprietary trading and quantitative algorithms (now Tickeron&rsquo;s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional,&nbsp;sophisticated stock market analysis capabilities to retail investors via&nbsp;an easy-to-use interface.</p>


LWLG's Stochastic Oscillator is sitting in overbought zone for 3 days

The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LWLG declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

LWLG broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for LWLG entered a downward trend on August 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LWLG's RSI Indicator exited the oversold zone, of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on July 31, 2026. You may want to consider a long position or call options on LWLG as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for LWLG just turned positive on July 21, 2026. Looking at past instances where LWLG's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where LWLG advanced for three days, in of 284 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LWLG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.361) is normal, around the industry mean (7.256). P/E Ratio (0.000) is within average values for comparable stocks, (39.219). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.443). LWLG has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.019). LWLG's P/S Ratio (5000.000) is very high in comparison to the industry average of (95.488).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LWLG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.

Notable companies

The most notable companies in this group are DuPont de Nemours (NYSE:DD), Chemours Company (The) (NYSE:CC).

Industry description

The specialty chemicals sector includes companies that produce chemicals and industrial gases, which are of relatively high-value, often made to customer specifications. Examples of specialty chemicals are electronic chemicals, industrial gases, coatings, adhesives and sealants, industrial and institutional cleaning chemicals. The products are often valued on the basis of their purposes/performances rather than for their composition. Linde Plc, Ecolab Inc., Air Products and Chemicals, Inc., and Dow, Inc. are some of the largest companies making specialty chemicals.

Market Cap

The average market capitalization across the Chemicals: Specialty Industry is 12.14B. The market cap for tickers in the group ranges from 47 to 225.87B. LIN holds the highest valuation in this group at 225.87B. The lowest valued company is GTBT at 47.

High and low price notable news

The average weekly price growth across all stocks in the Chemicals: Specialty Industry was 7%. For the same Industry, the average monthly price growth was 5%, and the average quarterly price growth was 9%. MATV experienced the highest price growth at 48%, while ECVT experienced the biggest fall at -14%.

Volume

The average weekly volume growth across all stocks in the Chemicals: Specialty Industry was -22%. For the same stocks of the Industry, the average monthly volume growth was -26% and the average quarterly volume growth was -9%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 57
Price Growth Rating: 50
SMR Rating: 78
Profit Risk Rating: 81
Seasonality Score: -18 (-100 ... +100)
View a ticker or compare two or three
LWLG
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry ChemicalsSpecialty

Profile
Details
Industry
N/A
Address
369 Inverness Parkway
Phone
+1 720 340-4949
Employees
34
Web
https://www.lightwavelogic.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.